Investor Presentaiton

ANDA Pipeline - Significant ramp up. ANDAS Filed and Approved 597 584 572 561 478 449 438 427 422 413 397 344 311 250 FY12 FY13 FY14 FY15 FY16 FY17 FY18 I Cumulative Products Filed Cumulative Products Approved (Cumulative no's for FY16 are lower than FY15 due to Bryan facility divestment. Taro numbers added since Mar 2011, URL numbers added since Mar 2013 & Ranbaxy numbers added for March'15) © Sun Pharmaceutical Industries Limited. All Rights Reserved. SUN PHARMA 422 ANDA Approvals by Therapeutic Area 110 97 CVS 00 60 46 30 19 15 12 7 26 Pain Allergy Oncology Metabolism Antibiotic Gastro Other (As of March'18) 19

View entire presentation